Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Venom immunotherapy (VIT) is indicated for all individuals with sting-induced anaphylaxis and evidence of venom-specific IgE. For patients with a concurrent proliferative mast cell disorder, such as monoclonal mast cell activation syndrome (MMAS) or mastocytosis, which confer increased risk of venom allergy, life-long VIT has been recommended on the basis of case reports that describe fatal anaphylaxis due to field stings after discontinuation of VIT. Elevated baseline serum tryptase in the setting of sting-induced anaphylaxis, including but not exclusively in mastocytosis, confers an increased risk of anaphylaxis during VIT. Several case reports have indicated the efficacy of omalizumab, a humanized monoclonal IgG1 anti-IgE Fce antibody in mitigating the risk of anaphylaxis in high-risk settings during VIT. This has been demonstrated by using both pretreatment and maintenance omalizumab dosing to treat patients at high risk without mastocytosis who were receiving modified rush or ultrarush VIT, and both during initiation of modified rush and as high-dose monthly therapy during maintenance VIT in individuals with mastocytosis. However, not all case reports support the efficacy of omalizumab during immunotherapy, and it remains unclear as to what other factors, apart from the kind of protocol used and the presence or absence of monoclonal mast cell disorders contribute to clinical success. An accepted mechanism of action is via downregulation of FceRI in response to depletion of circulating IgE, thereby reducing mast cell responsiveness. However, a clinical report that described the efficacy of omalizumab in sting-induced anaphylaxis in a patient with mastocytosis but without demonstrable venom-specific IgE suggests that, despite the lack of cellular evidence, an additional mechanism of action, such as mast cell apoptosis via reduced IgE binding with subsequent reduction in mast cell burden, cannot be discounted. We describe a case of omalizumab used to mitigate anaphylaxis during ultrarush honey bee VIT in a patient with MMAS. This case is unique in that the target dose of 100 mg was safely attained within 3 days, with maintenance doses continued safely thereafter for more than 12 months to date, even after omalizumab therapy had been stopped.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bonadonna, P., Perbellini, O., Passalacqua, G., Caruso, B., Colarossi, S., Dal Fior, D., Castellani, L., Bonetto, C., Frattini, F., Dama, A., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.11.018 · Cited by 392
Oude Elberink, J. N. G., de Monchy, J. G. R., Kors, J. W., van Doormaal, J. J., & Dubois, A. E. J. (1997) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(97)81058-5 · Cited by 203
Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab
Schulze, J., Rose, M., & Zielen, S. (2007) · Allergy · doi:10.1111/j.1398-9995.2007.01388.x · Cited by 74
Cited by
Stinging insect hypersensitivity
Golden, D. B. K., Demain, J., Freeman, T., Graft, D., Tankersley, M., Tracy, J., Blessing-Moore, J., Bernstein, D., Dinakar, C., Greenhawt, M., et al. (2017) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2016.10.031 · Cited by 267
Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management
Castells, M., & Butterfield, J. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.02.002 · Cited by 135
Weiler, C. R., Austen, K. F., Akin, C., Barkoff, M. S., Bernstein, J. A., Bonadonna, P., Butterfield, J. H., Carter, M., Fox, C. C., Maitland, A., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.023 · Cited by 123
Valent, P., Hartmann, K., Schwaab, J., Alvarez-Twose, I., Brockow, K., Bonadonna, P., Hermine, O., Niedoszytko, M., Carter, M. C., Hoermann, G., et al. (2022) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2022.03.007 · Cited by 72
Mast cell activation syndromes: Collegium Internationale Allergologicum update 2022
Valent, P., Hartmann, K., Bonadonna, P., Niedoszytko, M., Triggiani, M., Arock, M., & Brockow, K. (2022) · International Archives of Allergy and Immunology · doi:10.1159/000524532 · Cited by 55
Metadata
- Authors
- da Silva, E. N., & Randall, K. L.
- Venue
- The Journal of Allergy and Clinical Immunology: In Practice
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 1
- Issue
- 6
- Pages
- 687-688
- ISSN
- 2213-2198 (ISSN-L)
- OpenAlex
- W2081196283
- Cited by
- 45
- References
- 3
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.